Lab21 hires cfo

Susan Lowther joins Cambridge, UK-based firm

Lab21, a Cambridge, UK-based specialist in personalised medicine, has hired Susan Lowther as chief financial officer.

Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.

Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’

You may also like

Research & Development

Lab21 sells South Carolina laboratory operations

Will continue to focus on diagnostic content opportunities within the US market
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Distribution

Genesis Pharma to distribute Santhera's Agamree for DMD

The therapeutic recently received EC approval to treat patients over 4 years old with Duchenne muscular dystrophy
Pharmaceutical

At Pack Expo 2024, Antares Vision Group to debut versatile, high-speed serialization station for pharma bottles of various shapes and sizes

Antares Vision Group will also introduce a serialization module for flat cartons and demonstrate a high-speed automated visual inspection unit for liquid-filled vials
Pharmaceutical

CPHI Milan announces the finalists for 14 categories of the Pharma Awards

Awards for future leaders, women of the year and those at the heart of pharma will be handed out at the CPHI Pharma Awards ceremony
Subscribe now